Alumis and ACELYRIN reaffirm all-stock merger; pro forma cash ~$737M

ALUMIS INC.

Alumis and ACELYRIN reaffirm commitment to merge in an all-stock transaction expected to close Q2 2025.
Pro forma cash of ~$737M as of Dec 31, 2024 provides runway into 2027.
Alumis had ~$289M cash, ACELYRIN ~$448M (preliminary, each as of Dec 31, 2024).
Combined portfolio includes ESK-001 (psoriasis, lupus), lonigutamab (thyroid eye disease), A-005 (multiple sclerosis).
Transaction subject to stockholder approvals and customary closing conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.